BioMarin Completes Rolling NDA Submission to FDA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
April 27, 2015 at 09:44 AM EDT
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced completion of the rolling submission of a New Drug Application (NDA) to the ...